[PE26] Poster Session 26
Other skin diseases 1

[PE26-11] Efficacy and safety of Ligelizumab for CSU in Japanese patients: subgroup analysis of phase 2b study

Michihiro Hide¹, Atsushi Fukunaga², Mami Murakami³, Eva Hua⁴, Thomas Severin⁵, Reinhold Janocha⁵, Atsuyuki Igarashi⁶ (1.Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Japan, 2.Department of Dermatology, Kobe University, Japan, 3.Novartis Pharma K.K., Japan, 4.Shanghai Novartis Trading Ltd., China, 5.Novartis Pharma AG, Switzerland, 6.NTT Medical Center, Japan)